Enzi G, Baritussio A, Marchiori E, Crepaldi G
J Int Med Res. 1976;4(5):305-18. doi: 10.1177/030006057600400504.
The effectiveness and tolerance of a non-amphetaminic anorexiant drug has been evaluated in a short-term and in a long-term clinical trial in simple obesity and in refractory obesity. In the short-term 'crossover' trial, a more evident effectiveness and tolerance result when the anorexiant is given in a late phase of treatment. The association of an anorexiant drug with the hypocaloric diet was seen to be effective in the treatment of so-called refractory obesity. In the evaluation of the long-term treatment it is seen that weight loss is greater and remains so farr longer periods in patients receiving anorexiant, as compared to controls. This is related to a better maintenance of a restricted calorie regimen. Mazindol did not affect the improvement of glucose tolerance and insulin secretion which follows the weight reduction.
一种非苯丙胺类食欲抑制剂药物在单纯性肥胖和难治性肥胖的短期及长期临床试验中，对其有效性和耐受性进行了评估。在短期“交叉”试验中，当食欲抑制剂在治疗后期给药时，有效性和耐受性结果更为明显。食欲抑制剂药物与低热量饮食联合使用被认为对治疗所谓的难治性肥胖有效。在长期治疗评估中发现，与对照组相比，接受食欲抑制剂治疗的患者体重减轻更多且维持时间更长。这与更好地维持热量限制方案有关。马吲哚不影响体重减轻后葡萄糖耐量和胰岛素分泌的改善。
